Title:
MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE
Document Type and Number:
WIPO Patent Application WO/2023/212646
Kind Code:
A3
Abstract:
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to wild-type and/or mutant nucleophosmin 1 located on the surface of cells. These antibodies, as well as antibody conjugates comprising these antibodies, are useful for the detection and treatment of cancers in which NPM1 is expressed on the surface of cancer cells.
Inventors:
FLYNN RYAN (US)
GEORGE BENSON (US)
TZELEPIS KONSTANTINOS (GB)
GEORGE BENSON (US)
TZELEPIS KONSTANTINOS (GB)
Application Number:
PCT/US2023/066299
Publication Date:
November 30, 2023
Filing Date:
April 27, 2023
Export Citation:
Assignee:
CHILDRENS MEDICAL CT CORP (US)
CAMBRIDGE ENTPR LTD (GB)
CAMBRIDGE ENTPR LTD (GB)
International Classes:
C07K16/30; A61K39/00; A61P35/00
Foreign References:
| US20210283178A1 | 2021-09-16 |
Other References:
DATABASE PROTEIN ANONYMOUS : "exported hypothetical protein [uncultured Eubacteriales bacterium]", XP093116026, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "immunoglobulin heavy chain variable region, partial [Mus musculus]", XP093116028, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "immunoglobulin heavy chain junction region, partial [Homo sapiens]", XP093116029, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "immunoglobulin heavy chain variable region, partial [Mus musculus]", XP093116028, retrieved from NCBI
DATABASE PROTEIN ANONYMOUS : "immunoglobulin heavy chain junction region, partial [Homo sapiens]", XP093116029, retrieved from NCBI
Attorney, Agent or Firm:
JULIAN, Victoria, L. et al. (US)
Download PDF: